BrainsWay Deep TMS Study Shows 70% Reduction in Suicidal Ideation
BWAY has more than doubled off its 52-week low of $7.135.
Summary
BrainsWay published peer-reviewed data showing a 70% reduction in suicidal ideation among MDD patients treated with Deep TMS, with faster improvement using the SWIFT accelerated protocol.
Key Events · Product Development and Regulatory · BWAY
-
70% Reduction in Suicidal Ideation
Peer-reviewed secondary analysis in Journal of Affective Disorders showed patients exhibiting suicidal ideation (SSI>0) fell from 22.5% (20/89) at baseline to 6.7% (6/89) after 6 weeks of Deep TMS — a 70% relative reduction.
-
SWIFT Protocol Faster Improvement
Median time to improvement in suicidality was 10 days with SWIFT accelerated protocol versus 13 days with standard Deep TMS, a statistically significant difference.
-
Growing 2026 Evidence Base
Results add to a separate randomized sham-controlled study and a 108-study review published in 2026, both supporting TMS for reducing suicidal ideation.
-
Not FDA-Cleared for Suicidality
Deep TMS is FDA-cleared for MDD, OCD, and smoking addiction, but not for treatment or prevention of suicidal ideation or behavior.
Analysis · BWAY · Industrial Applications And Services
New peer-reviewed data shows Deep TMS reduced the proportion of MDD patients exhibiting suicidal ideation from 22.5% to 6.7% over 6 weeks — a 70% relative reduction. The SWIFT accelerated protocol achieved improvement in a median of 10 days versus 13 days for standard treatment, a statistically significant difference. This adds to a growing 2026 evidence base supporting Deep TMS for suicidality, a high-unmet-need area. The data is not FDA-cleared for suicidal ideation, but it strengthens the clinical narrative and could support future label expansion and reimbursement discussions.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 29.9% of the 1591 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.24%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BWAY was trading at $14.62 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $586.2M. The 52-week trading range was $7.14 to $17.40. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.